Eyenovia enters non-binding LOI for reverse merger with Betaliq; EYEN holders to own ~16.3%

HYPERION DEFI, INC.

Reverse merger: Betaliq stockholders would own ~83.7% of combined company; Eyenovia holders ~16.3% on fully diluted basis.
Betaliq valued at ~$77M, Eyenovia at ~$15M (net cash zero at close); Eyenovia had $2.1M cash as of Dec 31, 2024.
Exclusivity period ends May 16, 2025; conditions include due diligence, definitive agreement, board approvals, and financing.
Combined company would continue marketing Eyenovia's FDA-approved products and leverage EyeSol+Optejet technologies.
Eyenovia expects to change name to Betaliq and update trading symbol; no assurance deal will close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.